Back to Dashboard
PCVX · Healthcare

VAXCYTE INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Bearish — money moving out

No standout activity across the feeds we track.

Hedge funds
26
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in VAXCYTE INC? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$8.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About VAXCYTE INC

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein…

Who's behind the signal
Every informed buyer we can see on PCVX, across all three feeds.
Hedge funds · 5
AQR Capital Management New position
Citadel Advisors Increased +59%
D.E. Shaw & Co Decreased −15%
Point72 (Steve Cohen) Decreased −77%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. VAXCYTE INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
1
New positions
1
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
New position
% of portfolio
0.0%
Position change
NEW
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
Increased +59%
% of portfolio
0.0%
Position change
+59%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
Decreased −15%
% of portfolio
0.1%
Position change
−15%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
Decreased −77%
% of portfolio
0.0%
Position change
−77%
0.0% of Point72's portfolio
Trust weight: 1.0×
Decreased −55%
% of portfolio
0.0%
Position change
−55%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to VAXCYTE INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell VAXCYTE INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime